Hexarelin
Overview
A synthetic hexapeptide growth hormone secretagogue with the highest GH-releasing potency among GHRPs. Hexarelin binds both GHS-R1a and CD36 (scavenger receptor), giving it unique cardiovascular properties independent of GH release. It exhibits cardioprotective effects through reduced atherosclerotic plaque formation and improved cardiac contractility via direct myocardial receptor activation.
Key Research Findings
Clinical trials demonstrated the most potent acute GH release among GHRPs. Unique CD36-mediated cardiovascular effects include improved cardiac output in heart failure patients and reduced lipid accumulation in macrophages. Subject to significant tachyphylaxis with chronic dosing, limiting long-term utility for GH augmentation (Broglio et al., J Endocrinol Invest, 2005).
Subcutaneous injection, Intravenous
Investigational
Interested in Hexarelin?
Find a verified provider experienced with Hexarelin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Hexarelin ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.